Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Visanne · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Visanne (SH T00660AA , BAY86-5258) | DRUG | Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients |
| Visanne (BAY86-5258, SH T00660AA) | DRUG | orally once daily |
| Placebo | DRUG | orally once daily |
Inclusion Criteria: * Female patients with endometriosis-associated pelvic pain Exclusion Criteria: * Pregnant or lactating women * History or suspicion of hormone dependent tumor * Therapy resistant endometriosis or need for primary surgical treatment * Any other conditions which forbid the part...
Visanne is an investigational small molecule being developed for the treatment of endometriosis. It is currently in Phase 3 clinical development, meaning it has not yet been approved and remains under study. The drug is being evaluated in adult female patients with endometriosis.
Visanne is being developed by Bayer AG, a pharmaceutical company traded under the ticker BAYRY. Bayer is conducting the clinical development program for this investigational drug, which is being studied as a treatment for endometriosis.
Visanne is in Phase 3 clinical development. It is an investigational drug, not yet approved, and is being studied for the treatment of endometriosis. Two Phase 3 trials have been completed as part of its clinical program.
Visanne has been studied in two completed Phase 3 clinical trials: NCT00225186 and NCT00225199. Both trials evaluated the safety and efficacy of the drug in treating endometriosis. The first trial enrolled 168 participants in Germany, Italy, and Ukraine, while the second enrolled 198 participants.
Yes, Visanne is also known as SH T00660AA. The clinical trials for this drug, including NCT00225186 and NCT00225199, use the name SH T00660AA in their titles. Both names refer to the same investigational drug being developed for endometriosis.